SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Processing: Top Headlines

UPDATE

Novartis: New cost-saving unit will not target manufacturing network

Novartis has reduced its network by 24 plants since 2010

29-Jan-2015 - Novartis has divested, restructured, or mothballed 24 manufacturing plants since 2010 but says its new NBS cost-saving business will not focus on streamlining and consolidating sites.

Related news

News in brief

Hospira 'committed to quality' as total recall count hits 40 since 2012

27-Jan-2015 - A human hair found in a vial of Sodium Chloride Injection has led to the fortieth recall in three years for Hospira.

Halal and Kosher stamps of approval for pregnancy drug

26-Jan-2015 - A morning sickness drug made by Duchesnay USA will now display Halal and Kosher symbols – a move the company said is the first case of Kosher certification for an oral prescription drug in the US.

Teva: More biomanufacturing space needed to tap biologics opportunities

21-Jan-2015 - Teva must invest in its biomanufacturing network as the firm’s biologics aspirations grow beyond biosimilars, CEO Erez Vigodman told investors.

Cost, not compliance, behind Clayton closure, says Hospira

19-Jan-2015 - Hospira has announced it will close its plant in Clayton, North Carolina that it no longer deems cost effective for drug production.  

Novartis to close Puerto Rico plant and outsource to Eli Lilly

19-Jan-2015 - Novartis will close an OTC plant in Puerto Rico by 2019 and transfer manufacturing and packaging actives to sites in the US and facilities operated by Eli Lilly and Virbac.

J&J to receive almost €50m in grants to help manufacture Ebola vaccines

19-Jan-2015 - EFPIA has given J&J subsidiary Crucell Holland and partner Bavarian Nordic €47.6m ($54.9m) to accelerate development of an candidate Ebola vaccine.

Fresenius Kabi NY aseptic plant upgraded by USFDA

15-Jan-2015 - A Fresenius Kabi plant in New York has been upgraded, and up to five new products could receive FDA approval, almost three years after receiving a warning letter.

Processing: Featured news

Spotlight

'On Immunity': enter BioPharma-Reporter.com’s free book giveaway
Competition

'On Immunity': enter BioPharma-Reporter.com’s free book giveaway

Did you know that throughout the nineteenth century, vaccination left a scar known as “the mark of...

Illicit vendors using YouTube to advertise fake drugs, says MHRA

Illicit vendors using YouTube to advertise fake drugs, says MHRA

Regulatory enforcement saw fewer counterfeit drug websites in 2014 but sellers are turning to YouTube and social...

Resistance is…years away: New compound could delay post antibiotic era

Resistance is…years away: New compound could delay post antibiotic era

Discovering a new antibiotic candidate and finding out how it kills superbugs without letting resistant mutants escape...

Oil's well that ends well? Low Brent crude price a boon for pharma says analyst

Oil's well that ends well? Low Brent crude price a boon for pharma says analyst

Falling oil prices will cut drug industry materials, manufacturing and logistics costs, and protect firms at risk...

Gilead strikes back at AbbVie with exclusive payer deal for hep C drug

US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments

Gilead and AbbVie’s exclusive deals with payers CVS and Express Scripts could help cut the cost of...

Not prepared for track & trace? US FDA grants amnesty until May

Not prepared for track & trace? US FDA grants amnesty until May

The US FDA will give drugmakers and distributors until May to comply with new track and trace...

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...